International Alliance for Biological StandardizationMay 15-17, 2019 - Wiesbaden, Germany
Workshop on
Diagnostics in the Veterinary Field:
The Role in Health Surveillance and Disease Identification
Registration and information about the meeting here
A workshop focusing on advantages / benefits and disadvantages
and gaps of the current methods and methodologies
5th Statistical Approaches for CMC Development and Lifecycle Management of Biotherapeutics and Vaccines
5th Statistical Approaches for CMC Development and
Lifecycle Management of Biotherapeutics and Vaccines
November 26-28, 2018
Venue: US Pharmacopeia
Rockville, Maryland
Objectives
This meeting is to bring together regulators and scientists to discuss statistical approaches used to help develop and manage processes, which ensure the quality and availability of biotherapeutics and vaccines. Speakers and panel members will engage with meeting participants on challenges and solutions related to CMC development and lifecycle management of biologics. Areas of attention will include Quality by Design in process and analytical development, comparability and biosimilarity, stability study design and analysis, validation, and continuous process and analytical verification. Statistical challenges related to introduction of new technologies and Big Data will be discussed. Special emphasis will be devoted to collaboration and communication, between scientists and statisticians as well as industry and regulators. The meeting will bring experts together to discuss the issues and through roundtables attempt to reach conclusions that will add value to global public health.
Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing
Workshop: Implementing Non-animal Approaches to Human and Veterinary Vaccine Testing:
Achieving Scientific and Regulatory Success for Rabies and Beyond
October 16-17, 2018
National Institutes of Health, Bethesda, Maryland
The workshop agenda as well as speaker and poster abstracts are included in the e-book. The e-book and speaker slides are posted on the web (e-book* and slides**).
Read more: Implementing Nonanimal Approaches to Human and Veterinary Vaccine Testing
Narcolepsy and Pandemic Influenza Vaccination
Narcolepsy and Pandemic Influenza Vaccination
What we know and what we need to know before the next Pandemic
March 26-27, 2018
Eurostation II, Place Victor Horta
Brussels, Belgium
In partnership with
Federal Agency for Medicines and Health Products (FAMHP)
Vaccine Center of Excellence
This meeting will be held under Chatham House Rule
Influenza Pandemics occur when an influenza strain circulates that humans have not been exposed to before. This may lead to widespread circulation and a high case fatality rate.
In 2009 pandemic, several H1N1 vaccines were developed against the new H1N1 virus and were extensively used. In Finland and Sweden an increase in narcolepsy was noted after the mass vaccination with one of these vaccines. Disparate results were seen in other countries with other vaccines. In addition, an increase of narcolepsy has been reported in countries in Asia following wild type influenza infection.
The goal of this meeting is to be prepared for the next pandemic:
- What are the latest data on the risk of narcolepsy following exposure to 2009 pandemic vaccines?
- What scientific data are available and what data are lacking to explain the phenomena that was seen in 2009-10?
- What additional work is needed to prepare for potential use of adjuvanted vaccines for a future pandemic ?
4th Cell Therapy Conference
4th Cell Therapy Conference
Manufacturing and Testing of Pluripotent Stem Cells
Organized by
The International Alliance for Biological Standardization
IABS
with support from and in collaboration with the
California Institute for Regenerative Medicine
CIRM
Los Angeles, California
June 5-6, 2018
Objectives and Expected Outcomes
The 2018 Cell Therapy conference will identify key unresolved issues that need to be addressed for the manufacture and testing of pluripotent stem cell-based therapies and provide scientific consensus on selected aspects to inform the drafting of future national and international guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.
The overall goal of the conference is to provide the target audience with an appreciation of the importance of a well-controlled manufacturing process for cell therapies that are in development, and to highlight specific areas that should be considered during early product development in order to avoid issues in later stages. The target audience includes those individuals and organizations actively pursuing research and development of cell therapies with the intent of achieving pluripotent stem cell therapy products that meets regulatory requirements for approval, thus becoming generally available to treat patients with unmet medical needs.
We will build on previous meetings that generally addressed broader themes of cell therapy studies and manufacturing issues. In addition to reviewing information on the state-of-the-art and recently generated data, this conference ill drill down to key practical issues facing cell therapy developers and regulators to expedite the safe and efficient introduction of new treatments for important diseases where unmet medical needs exist.
More specifically, the conference is expected to provide a basis for new and/or additional guidance on regulatory expectations for developing acceptable pluripotent cell therapy products including testing requirements during manufacture. Concrete conclusions and recommendations will be important outcomes, which are expected to stimulate the field to move forward in a transparent and coordinated manner.
September 25-26, 2017 - University of Ghent, Belgium
Autogenous Vaccines and Their Role
in Animal Health Strategy
September 25-26, 2017
Venue: Het Pand, University of Ghent
Co-organized by IABS-EU and University of Ghent / PROVAXS
The purpose of this conference is to start from an overview on the current situation and needs from the perspective of regulators, scientists, manufacturers and the end-user (veterinarians). The main focus will be on food producing animals, including fish. Further, proposals will be presented for a harmonized approach which will lead to a better understanding of the rational for the intended use, better knowledge on the nature of isolates and improved production and quality of the final products. In addition, advanced techniques and methods will be presented and discussed to identify and propagate isolates, to upgrade production and to quickly estimate safety and even efficacy of autogenous vaccines by in vitro methods.
Recommendations will be drafted on how to improve the EU-legislation and communication between the EU-Member States on autogenous vaccines and on ways to increase transparency on quality and safety of the vaccines.
Read more: September 25-26, 2017 - University of Ghent, Belgium
Advancing Analytics for Biotechnology Products
Advancing Analytics for Biotechnology Products
An IABS - FDA international meeting
co-sponsored by NIST
Venue: NIST, Gathersburg, Maryland
Green Auditorium
Gathersburg, Maryland
November 6-8, 2017
This meeting is to bring together regulators, and scientists, or those interested in analytics from academia and industry to help resolve existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use current and novel analytics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability and process development and execution will be provided by the speakers and panel members. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.
NON U.S. CITIZENS PLEASE NOTE: All foreign national visitors must supply additional information. Failure to provide this information prior to arrival will result in significant delays in entering the facility. Authority to gather this information is derived from United States Department of Commerce Department Administrative Order (DAO) number 207-12. Please fax the following NIST 1260 form to Myesha Steadman as soon as registration is complete: fax (301) 975-4629.
4th Statistical and Data Management Approaches for Biotechnology Drug Development
4th Statistical and Data Management Approaches
for Biotechnology Drug Development
Venue: USP Pharmacopeia, Rockville, Maryland
October 30 - November 1, 2017
This meeting is to bring together regulators, and scientists, or those interested in statistics from academia and industry, who have a background in statistics, to help resolve existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use statistics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability, biosimilarity exercises and stability program development will be provided by the speakers and panel members. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.
Click here to learn more about the meeting
October 26-27, 2017 - USP Pharmacopeia, Rockville, Maryland
Next Generation Sequencing for
Adventitious Virus Detection in Biologics
Venue: USP Pharmacopeia, Rockville, Maryland
October 26-27, 2017
The 2017 NGS conference will discuss current perspectives on NGS for adventitious virus detection in biologics with focus on applications for human vaccines and lessons learnt from veterinary vaccines. The meeting will include data presentations and discussions for developing a scientific consensus to draft points for consideration for using NGS for virus detection in selected applications of biologics. The meeting will bring together representatives from industry, academia, service providers, and regulatory bodies.
September 28-30, 2017 - Rockville, Maryland, USA
2nd Human Challenge Trials Conference
Venue: Hilton Hotel, Rockville, Maryland
September 28-30, 2017
Our world needs safer, more effective drugs and vaccines to prevent and treat infectious diseases. Controlled human infections (CHIs) have served as an effective tool to promote this objective. For example, CHIs have led to progress in developing interventions against respiratory pathogens, enteric pathogens, and parasites. The most frequent application is the conduct of human challenge trials (HCTs), which can safely assess the value of novel or improved drugs and vaccines much more rapidly and efficiently than field trials, particularly if efficacy against CHI bridges to the field. Progress against an infectious threat is greatly hampered when the field lacks a supporting human challenge model, such as is the case for human immunodeficiency virus and Mycobacterium tuberculosis.
Based on the premise that optimal use of CHIs is one of the best, most efficient ways to achieve rapid progress against infectious diseases, IABS is hosting a workshop to review the use of HCTs to promote the development of new drugs and vaccines, the benefits and risks of this approach, the regulatory framework within which HCTs are conducted, and novel CHI applications that would open new translational pathways. This workshop follows two and a half years after the first such workshop hosted by IABS in Strasbourg, France, September 2014.
18-19 February, 2015, Tokyo, Japan
International Regulatory Endeavour Towards Sound Development of Human Cell Therapy Products
Date: February 18-19, 2015
Venue: Hitotsubashi Hall
Organized by IABS with the support of Pharmaceuticals and Medical devices Agency (PMDA); Japan Science and Technology Agency (JST); National Institute of Biomedical Innovation (NIBIO); World Health Organization (WHO)
Under the auspices of Forum for Innovative Regenerative Medicine (FIRM); Japan Pharmaceutical Manufacturers Association (JPMA); The Japanese Scoiety for Regenerrative Medicine (JSRM)
Scope and objective:
This meeting will bring together an outstanding and diverse group of speakers from regulatory agencies, industry, and academia, all of whom are at the forefront of the cell therapy field.The major objective of the meeting is to highlight the important regulatory considerations that are unique to human cell therapy products, as well as to promote international dialogue and exchange of information and points of view in this evolving field.The scope of the cell therapy products that will be covered in this meeting are human cell derived and substantially manipulated cell therapy products (hCTPs). The meeting will also identify special points/issues to consider for specific type of products, as well as very critical points/issues for various type of products, which have to be resolved, improved, and/or developed in terms of sound scientific regulation in order to facilitate the availability of products in a rational and timely manner, and which will be valuable globally to public health.
29-30 September, 2015 - Rockville, Maryland
2nd Statistical and Data Management Approaches for Biotechnology Drug Development
Date: 29-30 September, 2015
Venue: US Pharmacopeia Conference Center, Rockville, Maryland
Organized by: IABS anad FDA
Scope and objective:
This meeting is to bring together regulators, scientists, academia and industry to help resolve existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use statistics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability, biosimilarity exercises and stability program development. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.
Among the challenges that will be explored :
- Statistical Challenges with showing Comparability and Biosimilarity (Equivalence, small data sets, tolerance intervals etc.)
- Using statistics for Assay Methods (Statistics for development, qualification, validation and transfer of methods)
- The use of statistics and modelling when using Quality by Design (DoE, Bayesian, partial least squares, prior knowledge data sets)
- Managing large and/or complex data sets (Large data sets for monitoring variation, complex analytical methods – Mass Spec, NMR, historical data sets)
12-13 November, 2015 - Rockville, Maryland
2nd Progress and Challenge in Protein Particles and Immonogenicity of Biotherapeutics
Date: 12-13 November, 2015
Venue: US Pharmacopeia Conference Center, Rockville, Maryland
Organized by: IABS and Health Canada
Scope and objective:
In 2009, IABS and FDA cosponsored a conference which focused on:
- the mechanism of protein folding
- the characteristics of sub visible and visible protein particles that may influence immunogenicity including the size, type (reversible, protein class), composition, amount, and conformational status)
- the risks associated with the propensity to generate immune responses including the route of administration, dose, and frequency, duration of administration and indication
- the factors that influence the formation of large protein aggregates and methods to reduce protein aggregation (approaches in formulation, and protein design) including case studies of occurrence of these particulates in manufacturing
- analytical methods that are useful in quantifying these particles and approaches to the design of suitable control strategies that mitigate the risk to product quality.
IABS and Health Canada will revisit these topics in light of what has been learned in the past 6 years. Progress in understanding the science of protein particle formation, the evolution of the analytical technologies for characterization and measurement of sub-visible protein particles, the advances in standardization of protein particle measurements, and their possible relationship of protein particle attributes to safety and efficacy of biotherapeutics will be highlighted. The goal of the meeting is to assess the progress of the past half-decade, and its implications for risk management during biotherapeutic product development.
29-30 March, 2016 - Bethesda, Maryland
Harmonized Safety Monitoring of Immunization Pregnancy
International Consensus Conference
March 29-30, 2016
National Institutes of Health
Bethesda, Maryland, USA
Aim
- The aim of this conference is to highlight progress in harmonizing safety monitoring of immunization in pregnancy and to develop consensus recommendations for a globally concerted approach.
Objectives
- To discuss new safety data from immunization in pregnancy studies
- To identify converging stakeholder needs and requirements for high quality data
- To review new standards and tools for safety monitoring, including terminology
- To build consensus on best practice guidance for monitoring vaccine safety in pregnancy
Outcomes
- Shared understanding of the challenges of monitoring immunization in pregnancy
- Shared understanding of potential solutions for a collaborative way forward
- Consensus on the need for a globally concerted approach
- Recommendations for a road map towards optimal safety data based on a globally harmonized approach
This conference is inspired by the work performed within the GAIA project by partners and volunteers worldwide. This meeting will bring together regulators, scientists, academia and industry experts to help resolve existing challenges of safety monitoring of immunization in pregnancy and to reach conclusions that will be valuable to a globally concerted approach.
28-30 September, 2016 - Budapest, Hungary
Emerging Diseases in Animals:
Strategies in Surveillance, Control and Eradication
Budapest, Hungary
28 - 30 September 2016
Co-organized by
-
IABS
-
Paul-Ehrlich-Institut
-
Hungarian National Food Chain Safety Office
Budapest, Hungary
Emerging animal diseases challenge the health of domestic and wild animals. These highly contagious or transmissible diseases may spread easily, irrespective of political and geographic borders. This spread is fostered by the increased global movement of domestic animals and food produced from animals, as well as by vectors such as man, wild animals, intermediate hosts, and contaminated materials of all kind. This spread is also influenced by other factors such as changes in climate.
Outbreaks of diseases in livestock have a negative impact on economies, individuals’ livelihood and quality of life, as well as global safety of food produced by animals.
Although there is permanent progress in the development of new vaccines against a wide range of diseases, emerging infections and transboundary spread pose specific challenges in terms of surveillance and prophylactic interventions.
The goal of this meeting, to be held in 2016, is to update current experience in the identification, tracking, and control of these animal diseases. This includes experience thus far with licensing of vaccines required for emergency situations or scenarios. An additional area of discussion will focus on fostering rapid availability of vaccines.
11-12 October, 2016 - USP, Rockille, Maryland
3rd Statistical and Data Management Approaches
for Biotechnology Drug Development
USP Headquarters, Rockville, Maryland
October 11-12, 2016
Co-organized by IABS and FDA
The 3rd annual stats & data management meeting will bring together regulators, and scientists, or those interested in statistics from academia and industry, who have a background in statistics, to continue exploring how best to resolving existing challenges in ensuring the quality of biotechnology medicinal products and to bring high quality medicines to patients. Guidance on how to use statistics for a variety of activities required during biotechnology product development such as method development, improvement and replacement, product comparability, biosimilarity exercises and stability program development will be provided by the speakers and panel members. In addition, the complexity of the types of data and the volume being analysed is ever increasing and how best to manage such data will be discussed. The meeting will bring the right experts together to discuss the issues and through roundtables attempt to reach conclusions that will be valuable globally to public health.
November 2-3, 2016 - London, United Kingdom
3rd IABS CONFERENCE on CELL THERAPY
MANUFACTURING AND TESTING
This meeting provided an important update on the
Regulation and Standardization of Cell Therapies
November 2-3, 2016
The Wellcome Collection
London, United Kingdom
The 2016 Cell Therapy conference will identify the key issues to be addressed for the manufacture of cell therapies and provide scientific consensus on selected aspects to inform the drafting of future guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.
It is intended that the conference output should provide core elements that will be useful in establishing international consensus on the requirements for manufacture of cell based medicines and enable progress towards a potential future WHO endorsed guidance.
folder Slides are available here
2014 Conferences
Click on the link for all the slides and meeting agenda :